Premium
The rationale for using apoA‐I as a clinical marker of cardiovascular risk
Author(s) -
BARTER P. J.,
RYE K.A.
Publication year - 2006
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.2006.01647.x
Subject(s) - medicine , cholesterol , apolipoprotein b , lipoprotein , high density lipoprotein , abca1 , efflux , risk factor , endocrinology , cardiology , biochemistry , biology , gene , transporter
. An inverse relationship between the concentration of high‐density lipoprotein (HDL) cholesterol and the risk of developing cardiovascular is well established. There are several documented functions of HDLs that may contribute to a protective role of these lipoproteins. These include the ability of HDLs to promote the efflux of cholesterol from macrophages and foam cells in the artery wall and to anti‐inflammatory/antioxidant properties of these lipoproteins. The fact that the main apolipoprotein of HDLs, apoA‐I, plays a prominent role in each of these functions adds support to the view that apoA‐I should be measured as a component of the assessment of cardiovascular risk in humans.